Given the earlier approvals of nivolumab and pembrolizumab for HCC, we collected data from patients who had previously received anti-PD-1 therapy to explore the efficacy of subsequent anti-PD-L1 treatment. This evidence concerns the gene CD274 and hepatocellular carcinoma.